BioDevelopment’s ORLAAM
Executive Summary
Drug Enforcement Administration transfers drug abuse treatment LAAM (levo-alpha-acetylmethadol) from Schedule I to Schedule II, effective Aug. 18. Those already in possession of LAAM must meet requirements by Sept. 17. LAAM was approved July 9 for the management of opiate dependence ("The Pink Sheet" July 19, T&G-1).